Creative Biolabs has developed a novel IVD platform to generate monoclonal, polyclonal, and recombinant antibodies for a wide range of diagnostic targets. Especially, we introduce our IVD antibody development services for IGFBP-7 marker. Our services are customized to suit the specific needs of our clients. We are confident that our commitment to science and research will enable us to offer you the best products and services.
Insulin-like Growth Factor-binding Protein 7 (IGFBP-7)
Insulin-like growth factor-binding protein 7, also known as mac25 or IGFBP-related protein-1 (IGFBP-rP1), is a member of the insulin-like growth factor (IGF)-binding protein (IGFBP) family, encoded by IGFBP7 gene. It regulates IGF availability in body fluids and tissues via binding to IGF with high affinity, inhibiting the binding of IGF and its corresponding receptors, thereby influencing the IGF signaling pathway. This signaling pathway is a very critical signal transduction pathway involved in many physiological activities, including associated with cells growth, differentiation, and apoptosis. IGFBP-7 also induces cell senescence and apoptosis by inhibiting BRAF/MEK/ERK signaling cascade. Besides, studies have been shown that IGFBP7 may be a tumor suppressor for breast, prostate, colorectal cancers, and melanoma. IGFBP-7 also stimulates prostacyclin production and cell adhesion.
Fig.1 Exploring mechanisms and pathways linked to IGFBP7 and cancer.1
IGFBP-7 Marker of Acute Kidney Injury (AKI)
AKI is an abrupt loss of kidney functions that develops within 7 days. It is a complex clinical syndrome associated with adverse clinical outcomes. It can influence various biological mechanisms involving immunity, inflammation, apoptosis, and cell cycle. However, early AKI is difficult to predict and identify.
Recent studies have been indicated that IGFBP-7 is a marker of G1 cell-cycle arrest. It can inhibit cell-cycle progress via influencing the activities of the cyclin-dependent protein-kinase complexes, resulting in G1 cell-cycle arrest. If individual cells are exposed to DNA damage during cell division, G1 cell-cycle arrest may block cell division. Only after the DNA damage is repaired will the cells continue to divide. Therefore, G1 cell-cycle arrest is a protective mechanism when cells are exposed to stress and injury.
During the early phase of cell injury, the G1 cell-cycle arrest will happen to protect cells from damage. And detection of G1 cell-cycle arrest may be regarded as a biomarker of imminent tubular damage in AKI. While the IGFBP-7, as a marker of G1 cell-cycle arrest, can be regarded as a promising predictor in early AKI and the IGFBP-7 levels rise up during the early period after renal tubular cell injury. Moreover, US Food and Drug Administration (FDA) has been approved IGFBP-7 levels as a predictive biomarker in early AKI.
Fig.2 Key principles in the pathophysiology of acute kidney injury.2
IVD Antibody Development Services for IGFBP-7 Marker
In order to render more precise antibody-based diagnostic tools and assist clinicians in the diagnosis, prognosis, and staging of different diseases and infections, Creative Biolabs provides customized IVD antibody development services to generate high-quality antibodies for diagnostic usage. Besides antibody generation, we also offer antibody conjugation, antibody pairing, and diagnostic immunoassay development services to our clients. For more detailed information, please feel free to contact us or directly send us an inquiry.
References
For Research Use Only.
